Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.55) per share. This is a 66.67 percent decrease over losses of $(0.33) per share from the same period last year.
HC Wainwright & Co. Reiterates Buy on Vericel, Maintains $37 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vericel (NASDAQ:VCEL) with a Buy and maintains $37 price target.